Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapy and small molecule product candidates to treat a range of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under development comprise DN24-02, an investigational cellular immunotherapy, which is in Phase II clinical trials for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; and carbonic anhydrase 9, an antigen expressed in renal cell carcinoma that is in preclinical development. The company is also developing carcinoembryonic antigen, an antigen in preclinical development, which is expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat multiple cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington.

Key Statistics